May 31, 2026, 10:02 AM EDT. A £13,000 investment in GSK (LSE: GSK) shares three months ago is now worth approximately £11,440, reflecting a 12% decline amid mixed sentiment. Despite sales rising 7% to £32.7 billion and core operating profit increasing 11% to £9.7 billion in full-year 2025 results, concerns over patent expiries, legal challenges, and sluggish vaccine sales have weighed on the stock. New CEO Luke Miels has signaled potential momentum with maintained growth targets, yet recent volatility persists. Investors remain cautious but note GSK's long-term prospects tied to ageing populations and strong U.S. market exposure, accounting for half of total revenue. The stock gained 27% year-on-year but recent dips highlight ongoing market uncertainty.
